Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.32 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288537 | 0.89 | MGAM (0.44) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8679475 | 0.82 | NAAA (0.37) | FFAR3MGAMGAASIMGAM2 | |
| SCHEMBL27994610 | 0.77 | CA2 (0.39) | FFAR3MGAMGAASIMGAM2 | |
| SCHEMBL2202426 | 0.75 | SMN1; SMN2 (0.40) | FFAR3MGAMGAASIMGAM2 | |
| SCHEMBL5996620 | 0.74 | TP53 (0.38) | FFAR3MGAMGAASIMGAM2 | |
| SCHEMBL9786775 | 0.72 | LDHA (0.33) | LDHASRR | |
| SCHEMBL7349937 | 0.72 | FFAR3 (0.47) | FFAR3MGAMGAASIMGAM2 | |
| SCHEMBL819956 | 0.71 | LDHA (0.53) | FFAR3MGAMGAASIMGAM2 | |
| SCHEMBL194638 | 0.71 | NAAA (0.32) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2037331 | 0.70 | FFAR3 (0.45) | FFAR3MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487468-B2 | Methylidene malonate process | OPTMED, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150203437-A1 | METHYLIDENE MALONATE PROCESS | OPTMED INC. (US) | 2015-07-23 | — | — | US | disclosed |
| US-8993795-B2 | Methylidene malonate process | OPTMED INC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130008773-A1 | METHYLIDENE MALONATE PROCESS | OPTMED, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2427422-A1 | IMPROVED METHYLIDENE MALONATE PROCESS | Optmed Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100286433-A1 | METHYLIDENE MALONATE PROCESS | OPTMED, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2010129066-A1 | IMPROVED METHYLIDENE MALONATE PROCESS | OPTMED INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286433-A1 | METHYLIDENE MALONATE PROCESS | MMAB, ME1, MAL2 | FFAR3 4357/4885MGAM 4/4885GAA 1095/4885 |
| US-20150203437-A1 | METHYLIDENE MALONATE PROCESS | MMAB, ME1, MAL2 | FFAR3 4357/4885MGAM 4/4885GAA 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.